225 related articles for article (PubMed ID: 32037196)
21. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
[TBL] [Abstract][Full Text] [Related]
22. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
Braga A; de Souza Hartung Araújo C; Mora PAR; Paulino E; de Melo AC; Velarde GC; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
Gynecol Oncol; 2020 Mar; 156(3):598-605. PubMed ID: 31928806
[TBL] [Abstract][Full Text] [Related]
23. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275.
Schink JC; Filiaci V; Huang HQ; Tidy J; Winter M; Carter J; Anderson N; Moxley K; Yabuno A; Taylor SE; Kushnir C; Horowitz N; Miller DS
Gynecol Oncol; 2020 Aug; 158(2):354-360. PubMed ID: 32460997
[TBL] [Abstract][Full Text] [Related]
24. Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.
Mangili G; Cioffi R; Danese S; Frigerio L; Ferrandina G; Cormio G; Rabaiotti E; Scarfone G; Gadducci A; Bergamini A; Pisano C; Candiani M
Gynecol Oncol; 2018 Dec; 151(3):449-452. PubMed ID: 30266260
[TBL] [Abstract][Full Text] [Related]
25. First line chemotherapy in low risk gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2009 Jan; (1):CD007102. PubMed ID: 19160319
[TBL] [Abstract][Full Text] [Related]
26. Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia.
Maestá I; Berkowitz RS; Goldstein DP; Bernstein MR; Ramírez LA; Horowitz NS
Gynecol Oncol; 2015 Jul; 138(1):50-4. PubMed ID: 25933681
[TBL] [Abstract][Full Text] [Related]
27. Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial.
Yarandi F; Mousavi A; Abbaslu F; Aminimoghaddam S; Nekuie S; Adabi K; Hanjani P
Int J Gynecol Cancer; 2016 Jun; 26(5):971-6. PubMed ID: 27101581
[TBL] [Abstract][Full Text] [Related]
28. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
Deng L; Zhang J; Wu T; Lawrie TA
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD005196. PubMed ID: 23440800
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
30. Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis.
Hoskins PJ; Le N; Kumar A; Pina A; Sabourin JN; Kim H; Osborne RJ
Gynecol Oncol; 2020 May; 157(2):367-371. PubMed ID: 32143915
[TBL] [Abstract][Full Text] [Related]
31. Postmolar choriocarcinoma: An independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia.
Strohl AE; Lurain JR
Gynecol Oncol; 2016 May; 141(2):276-280. PubMed ID: 26896825
[TBL] [Abstract][Full Text] [Related]
32. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial.
Lertkhachonsuk AA; Israngura N; Wilailak S; Tangtrakul S
Int J Gynecol Cancer; 2009 Jul; 19(5):985-8. PubMed ID: 19574798
[TBL] [Abstract][Full Text] [Related]
33. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
[TBL] [Abstract][Full Text] [Related]
34. Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy.
Jareemit N; Horowitz NS; Goldstein DP; Berkowitz RS; Elias KM
Gynecol Oncol; 2020 Dec; 159(3):751-757. PubMed ID: 33023756
[TBL] [Abstract][Full Text] [Related]
35. Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide.
Kanno T; Matsui H; Akizawa Y; Usui H; Shozu M
J Gynecol Oncol; 2018 Nov; 29(6):e89. PubMed ID: 30207097
[TBL] [Abstract][Full Text] [Related]
36. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC).
Verhoef L; Baartz D; Morrison S; Sanday K; Garrett AJ
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):458-463. PubMed ID: 28345753
[TBL] [Abstract][Full Text] [Related]
38. Single-dose actinomycin D: Efficacy in the prophylaxis of postmolar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole.
Uberti EM; Diestel MC; Guimarães FE; De Nápoli G; Schmid H
Gynecol Oncol; 2006 Aug; 102(2):325-32. PubMed ID: 16476471
[TBL] [Abstract][Full Text] [Related]
39. Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies.
Hao J; Zhou W; Zhang M; Yu H; Zhang T; An R; Xue Y
BMC Cancer; 2021 Oct; 21(1):1122. PubMed ID: 34663255
[TBL] [Abstract][Full Text] [Related]
40. Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia.
Chen LM; Lengyel ER; Bethan Powell C
Gynecol Oncol; 2004 Jul; 94(1):204-7. PubMed ID: 15262143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
